Search
BGB-DXP593
go.drugbank.com/drugs/DB16357Investigational[L27401] It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants … BGB-DXP593 is a SARS-CoV-2 neutralizing antibody.
SCIB1
go.drugbank.com/drugs/DB18439InvestigationalSCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma. … It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells.
AZD2389
go.drugbank.com/drugs/DB22104InvestigationalAZD2389 is an investigational small molecule inhibitor of fibroblast activation protein (FAP).[L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g. … NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).
Otilimab
go.drugbank.com/drugs/DB06303InvestigationalInvestigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).